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S U M M A R Y 
This literature review discusses the most frequently used serodiagnostic me-
thods for the determination of the humoral immune response to malarial parasites. 
The importance of malaria as a global public health problem is stressed in the 
light of the new discoveries leading to the future development of an anti-malarial 
vaccine suitable for use in humans. Serological techniques are expected to play 
an important role in the assessment of the relative efficacy of these candidate 
vaccines. A discussion of the different antigen preparation techniques is also 
presented. 
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Malaria, the parasites, and the disease. Hu-
man malaria is caused by infection with pro-
tozoans (Apicomplexa, Sporozoa) of the genus 
Plasmodium. Four species are known to infect 
man. P. falciparum is the most virulent species 
producing, in many cases, infections that lead 
to death. Frequently, the term "malignant" is 
used when clinicians refer to the malaria 
caused by this species. The other species, P. 
vivax, P. ovale, and P. malariae, have a more 
worldwide distribution and usually cause less 
severe infections. With the exception of P. 
malariae, human malarial parasites have a schi-
zogonous cycle ranging between 46 and 50 hours. 
P. malariae has a longer cycle, usually 72 hours 
(CAMPBELL and CHIN, 1981). 
. The life cycle of these species includes both 
asexual and sexual phases. In the asexual phase, 
which occurs in the vertebrate host, slender, 
spindle-shaped sporozoites inoculated through 
the bite of an infected Anopheles mosquito 
(Diptera, Culicidae) develop into pre-erythrocy-
tic stages in the parenchymal cells of the liver. 
Upon completion of this stage, merozoites are 
released and penetrate red blood cells. There 
follows several rounds of erythrocytic stages 
through schizogony with subsequent increase 
of the number of infected cells in circulation. 
Some of the ring forms develop into gametocy-
tes of either sex. When the susceptible mosquito 
takes its blood meal from the infected host, 
gametocytes are ingested, initiating the sexual 
cycle. Fertilization of the female gamete by the 
male takes place in the insect's stomach pro-
ducing an oocyst, which upon development 
releases a large number of sporozoites. After 
maturation, these sporozoites migrate to the 
salivary glands and are eventually inoculated 
into another susceptible host, thus completing 
the cycle. 
The pat tern of cyclic fever coinciding with 
the termination of each schizogonic cycle is a 
major clinical sign which has been historically 
associated with the disease. Early signs and 
symptoms, however, may be nonspecific — with 
fever occurring in no particular pattern, chills 
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ranging in intensity from mild-to-violent shud­
dering, headache, myalgia, and arthralgia — 
making up a set of signs and symptoms that 
resembles those caused by viral and some bac­
terial infections (CAMPBELL and CHIN, 1981). 
Other malaria parasites occur in several 
orders of vertebrates. Approximately 100 differ­
ent species have been described from reptiles, 
birds, bats, rodents, ungulates, and simians. 
Some simian Plasmodium species are infective 
to -man, and studies have been carried out 
because of the possibility of simian zoonotic 
malaria acting as an additional reservoir for 
human infection (KALRA, 1980). 
The global nature of malaria. Malaria is 
probably the number one parasitic disease 
affecting humankind. The morbidity and morta­
lity associated with the disease represent a 
tremendous threat to public health programs 
in developing countries (WYLER, 1983). 
Most of the significant advances in the 
biology, chemotherapy, and control of malaria 
have unfortunately emerged only as a conse­
quence of the two major world wars . During 
World War II and immediately thereafter, the 
scientific literature was enriched by almost as 
many publications about malaria as had been 
accumulated in the preceeding century. Additio­
nal and more effective insecticides, and sup­
pressive and curative drugs all emerged during 
intense basic and applied research programs 
worldwide (Most, 1974). Based on these techno­
logical advances the World Health Organization 
(WHO) in collaboration with the U.S. Agency 
for International Development (USAID) esta­
blished in the 1950s an aggressive program to 
eradicate human malaria from the world. Con­
siderable success had been attained in many 
of the developed countries earlier, where au­
tochthonous malaria was completely eradicated. 
The joint program had initial sucess in many 
countries, but its major ambition, worldwide 
eradication, was not fulfilled due to a combi­
nation of problems, many of which plague most 
of the developing nations, especially in the tro­
pics. Additionally, vectors and parasite strains 
genetically resistant to insecticides and drugs 
were gradually selected. 
Operational factors played an important 
role in retarding the effectiveness of the pro­
gram. Lack of adequate community health ser­
vices, scarcity of trained professionals, and 
administrative and political obstacles have con­
tributed to failure of malarial control measures 
in developing tropical countries. 
In the past 15 years many countries have 
witnessed almost complete failure of malaria 
control programs. The resurgence of the disease 
has affected nations in southern Asia and Latin 
America, not taking into account the highly 
endemic areas of Africa where precise figures 
have always been difficult to obtain (Anony­
mous, 1978). I t is estimated that the incidence 
of malaria on a worldwide basis now reaches 
150 million cases annually. Malaria prevails in 
most of tropical Africa where approximately 
one million children die annually from this 
disease (SPEER and SILVERMAN, .1979). These 
figures are higher than for any other parasitic 
disease. Considering humanitarian, social, and 
economic values, malaria probably remains the 
most important public health problem in the 
world today. 
One of the major reasons for resurgence 
of malaria has been negligence. During the mid 
1960s several countries relaxed control measures 
based on the assumption that residual cases 
did not deserve sustained effort and eradication 
would eventually be attained by general health 
services. Financial allocations were sharply re­
duced, and malaria task forces were fused with 
other general health programs. The increase in 
morbidity due to malaria and the problems 
that ensued have led to a reawakening of in­
terest in the disease as we see it today (WERNS-
DORFER, 1979). 
Due to renewed interest in the disease, in 
the mid 1970s WHO activated a special program 
for research and training in tropical diseases. 
This organization established as a primary goal 
an aggressive attack on six of the major ne­
glected diseases of mankind in which malaria 
has been included. Special working groups in 
malaria research were originally established for 
three different areas: chemotherapy (CHEMAL), 
immunology (IMMAL), and applied field re­
search (PIELDMAL). The targets of the stra­
tegy utilized by these programs are defined as: 
(i) reduction of malaria mortality to negligible 
levels, (ii) alleviation of the effects of the di­
sease on socio-economic development, and, ulti­
mately, (iii) eradication of malaria whenever 
feasible (Anonymous, 1978). 
The immune response to malarial parasites. 
There is currently a resurgence of interest in 
the immunology of malaria for several reasons. 
The development of an anti malarial vaccine 
appears as a viable proposition. An increased 
understanding of the role of the host 's response 
in acting synergistically with anti-malarial drugs 
has led scientists to new chemotherapeutic 
approaches (JAYAWARDENA, 1981). In addition, 
insights into the role of immunity in host-
parasite relationships and even host-tumor in­
teractions may be gained by studying the im­
mune response against malaria (JAYAWARDE­
NA, 1981). 
The complexity of the immune response to 
malaria is not surprising if we consider the 
complex life cycle of the parasite and its mode 
of existence within the vertebrate host. The 
magnitude and effectiveness of the immune 
response depends on the extent to which the 
antigenic makeup of the parasite triggers in­
dividual responses to individual antigens. The 
final outcome of such a chain of events within 
the host is a net balance between various single 
manifestations of the immune response, all of 
which may not be fully effective. An effective 
immune response that leads to a self-limiting 
infection is frequently seen in natural infec­
tions. For instance, P. knowlesi infection in 
rhesus monkeys — an unnatural host — is 
frequently fatal; this, in effect, eliminates both 
host and parasite. In its natural host, the kra 
monkey, however, P. knowlesi induces a level 
of immunity that allows long-lasting coexistence 
if both host and parasite (JAYAWARDENA, 
1981; RUITENBERG and BUYS, 1980). 
Extensive research in the last decade has 
led to the current view that both antibody and 
cell mediated immunity occur in the response to 
malarial infection. In 1969 Cohen et al. showed 
that immune serum inhibited the development 
of malarial parasites by acting on free mero-
zoites rather than on the intraerythrocytic 
forms. This experimental approach has been 
refined by other authors aiming at assaying 
specific immunity mediated by antibody (CAMP­
BELL et al., 1979; CHULAY et al., 1981; 
EPSTEIN et al., 1981; REESE and MOTYL, 
1979). Protection against infection in vivo can 
also be obtained by passive! transfer of anti­
malarial immune serum (Speer and Silverman, 
1979). Other experimental evidence for the role 
of B cells include the intensification of P. 
yoelii infection in animals with B cell activity 
suppressed by anti-IgM, and the induction of 
fatal P. gallinaceum infections (an otherwise 
fairly innocuous parasite) in bursectomized 
chickens (PLAYFAIR, 1978). The inhibition of 
erythrocyte invasion by merozoites has been 
shown to be mediated by species specific IgG 
and/or IgM antibodies; this interaction seems 
not to be complement dependent, since F (ab ) 2 
fragments of specific IgG also effect inhibition 
(COHEN, 1979). 
The level of protection conferred by anti-
merozoite serum is, nonetheless, not well cor­
related with its in vitro titer (Cohen, 1979). 
This is not surprising since the net balance of 
anti-malarial immunity may also involve cell-
mediated immunity. Development of protective 
immunity to malaria is clearly thymus de­
pendent. The triad of evidences supporting this 
view has been provided by JAYAWARDENA 
(1981): (i) T cell-deficient animals lack effective 
responsiveness to malaria, (ii) T cell activation 
plays an important role in development of 
immunity, and (iii) transfer of immunity from 
immune to nonimmune animals can be accom­
plished by T lymphocytes in a syngeneic system. 
The firs direct evidence that the thymus played 
a role in controlling malarial infections came 
from the demonstration that P. berghei infec­
tions were significantly more severe in rats 
that, were thvmectomized at bir th than in intact 
controls (BROWN et al., 1968; STECHSCHULTE, 
1969). The same phenomenon is observed in 
congenitally athymic mice (COHEN, 1979). Addi­
tionally, it was later demonstrated that recons-
titution with T cells restores the capacity of 
such animals to respond to infection (SPI-
TALSNY et al., 1977). Whereas there is little 
doubt that T cells are essential for generating 
an effective ariti-malarial immune response, very 
little is known of the manner by which these 
cells contribute to the development of the pro­
tective response. Close examination of the in­
tensity of infections (P. yoelii-mice) in animals 
of different major histocompatibility complex 
( M H O haplotypes has revealed no association 
between H-2 (mouse M H O and the outcome 
of the malarial infection (JAYAWARDENA, 
1981). This observation, however, does not rule 
on the possible role of MHC in the anti-Plas-
modium immune response because the com­
plexity of the response is always a product of 
both immunological and nonimmunological me 
chanisms which could ultimately mask some 
form of MHC-linked control. 
Recently, a new mechanism has been pro­
posed to explain the role of effector immune 
cells in anti-malarial immunity (ALLISON and 
EUGUI, 1982). The model proposed is based 
on the release of superoxide anion by macro­
phages and natural killer cells upon binding to 
parasitized red cells. This oxidant stress leads 
to degeneration of parasites within erythrocytes. 
Another macrophage-derived mediator acting 
under oxidized conditions is tumor-necrosis fac­
tor. This enzyme-like substance has been shown 
to inhibit multiplication of parasites in vitro 
(ALLISON and EUGUI, 1982). 
The only stages of the parasite that are 
immediately within reach of circulating antibo­
dies are the sporozoite and the merozoite. The 
other forms — rings, trophozoites, schizonts, 
and the intra-hepatocytic stages — are under 
various degrees of protection by cell membra­
nes which are generally impermeable to anti­
bodies. Gametocytes, on the other hand, are 
sexually specialized stages which may also be 
potential targets for humoral antibodies. I t 
has been both empirically and experimentally 
shown that the extra-cellular stages are poten­
tial sources of immunogenic preparations for 
vaccine use. 
As discussed above, the effect of anti-me-
rozoite antibodies in serum is inhibitory to 
erythrocyte invasion. It, therefore, became 
apparent that merozoites may be susceptible 
targets in order to achieve protection of the 
host by either active or passive immunization 
(FALANGA et al., 1982). The use of such parasite 
stages in preparation of vaccines is expected 
to induce protective immunity that prevents 
erythrocyte infection. Despite difficulty in achiev­
ing effective long-lasting protection with mala­
rial vaccines, some successful short-term im­
munization protocols have been presented 
(COHEN, 1979; COHEN et al., 1977; SPEER and 
SILVERMAN, 1979; SPEER et al., 1977). 
A different immunization approach that has 
also been the subject of intensive research is 
the use of sporozoite-derived vaccines. Effective 
immunization against sporozoites is believed to 
confer protection by the elimination of the 
parasites at the very moment of entrance into 
the host's body (MURPHY and LEFFORD, 1979; 
SPEER and SILVERMAN, 1979; SPEER et al., 
1977). One major assumption of this approach 
is that the vaccinated host will be able to 
neutralize 100% of the invading sporozoites or 
else will become infected, since protection is 
not conferred to the other stages. 
The third possible target in the parasite 
cycle is the garaetocyte. The feasibility of immu­
nizing against gametes for blocking mosqui­
to transmission has been recently reviewed 
(SPEER et al., 1977). In the typical model (P. 
gallinaceum-chicken) specific IgG antibodies in 
the immunized animals block fertilization in 
the insect midgut by immobilizing microgame-
tocytes. Although this approach of immunization 
does not protect the initial host against infec­
tion, since asexual multiplication can still occur 
(SPEER and SILVERMAN, 1979), this type of 
vaccine is gaining attention because of its 
possible use as a control measure in blocking 
transmission. 
Information in the literature has been frag­
mentary regarding the most appropriate pro­
tocols for vaccine administration. Major objec­
tives in experimentation with candidate vaccines 
have been compiled by SPEER et al. (1977). 
Ideally, a malaria vaccine should be; (i) capable 
of providing long-lasting protection against the 
species in question; (ii) free of host cell con­
tamination to avoid possible autoimmune res­
ponses; (iii) storable for reasonably long pe­
riods without losing potency; (iv) free of mi­
crobial contaminants; (v) easily mass-produced 
and transported by conventional methods; and 
(vi) free of undesirable side effects that could 
potentially outweigh its protective benefits. 
Recent studies have indicated the feasibility 
of vaccination with peptides from sporozoites 
of different species of Plasmodium. These pep­
tides have been show to be the target antigens 
of protective immunity. Genetic expression of 
cDNA encoding these peptides has been suc­
cessfully obtained in bacteria using suitable 
vectors. Libraries of genes encoding peptide 
fragments of both erythrocytic and sporozoite 
parasite stages have been established. Use of 
biosynthetic antigens from malarial parasites 
represent a great advantage over extracted an­
tigens. Genetically engineered immunogens can 
be obtained in large quantities and are re­
latively free of contamination with host subs 
tances. 
Cultivation. The bulk of the significant 
studies on vaccination against human and si­
mian malarial parasites has been contributed 
since 1976.' In that year Trager and Jensen pu­
blished the first successful method for conti­
nuous cultivation of erythrocytic stages of P. 
falciparum. Since then, the Trager-Jensen tech­
nique has: been used to cultivate strains of 
P. falciparum from different geographical areas 
around thé world. 
Parasites harvested from continuous culture 
provide a ready source of material for a variety 
of immunization protocols. Parasites from con­
tinuous culture can also be used as reagents 
for serological tests, thus abrogating the need 
for maintaining colonies of the valuable Aotus 
monkeys to be used as the source of infected 
blood. 
Basically, cultivation of P. falciparum is 
achieved by-, the use of a settled layer of human 
red cells in RPMI 1640 culture medium that 
has been supplemented with HEPES buffer, a 
gas phase of 2 to 3% C0 2 and low oxygen 
tension, and provision for a periodical change 
(24 hr) or ,a slow flow of medium over the 
layer of erythrocytes (TRAGER, 1980). Despite 
the various minor technical variants that have 
been successfully used in different laboratories, 
continuous cultivation is normally performed 
through two major methods: the continuous 
flow (TRAGER, 1979) and the candle jar (JEN­
SEN and TRAGER, 1977) techniques. 
In addition to P. falciparum certain simian 
malarias have been adapted to continuous cul­
ture ( C H I N e t al., 1979; NGUYEN-DINH et al., 
1980"', but there has been little or no success 
in cultivating the other three species of human 
malarial parasites. The literature has two 
accounts of presumably successfull at tempts in 
the cultivation of P. malariae in conjunction 
with P. falciparum (CHOWDHURI et al., 1980) 
and P. vivax alone (LARROUY et al., 1981). 
Unpublished' data from different laboratories 
have shown that these two species can undergo 
maturation in vitro for only a few schizogonic 
cycles with decreasing numbers of viable pa­
rasites during the period in culture. 
Antigen preparations. Various methods have 
been reported for the extraction and isolation 
of malarial antigens from parasites maintrained 
in culture or from infected blood of animals. 
KREIER (1977) has reviewed the existing me­
thods for isolation and fractionation of mala­
rial parasite-infected cells. He divided the most 
popular techniques into groups based on the 
principle of release of parasites from host cells. 
Kreier's classification categories include hypo­
tonic lysis; freezing and thawing; lysis with 
saponin, ammonium chloride, antiserum and 
complement; sudden decreases in pressure; ul­
trasound; and natural release. Each of these 
methods has intrinsic advantages and disadvan­
tages. Kreier found that continuous flow so-
nication combined with natural release of cul­
tured schizonts provide intact free parasites of 
all the erythrocyte developmental stages. The 
major disadvantage of continuous flow sonica-
tion is cost of the ultrasound cell disruptor 
which limits its application to those laborato­
ries most generously funded. 
The techniques mentioned above were de­
signed to be used with suspensions of infected 
cells of different stages of purification and 
enrichment. Depending on the concentration of 
infected cells and/or the relative abundance of 
a particular parasite stage, it may be necessary 
to treat the infected blood prior to release of 
parasites, to enrich the preparation and to 
isolate fractions containing, primarily, stages 
that are more relevant to the experiment. This 
is especially true of P. falciparum which in 
culture loses synchronicity within a few cycles 
even if the original inoculum contained para­
sites of only a single developmental stage. The 
Ficoll gradient centrifugation, PlasmagelTM j and 
gelatin methods are the most used to concen­
trate and isolate blood stage parasites. The for­
mer has been used to extract ring forms and 
to harvest merozoites from preparations but 
it is difficult to execute. The other two methods 
(JENSEN, 1979; REESE et al., 1979) are based 
on the principle of differential settling of para­
sitized red cells in a buffered solution of gelatin. 
Non-parasitized red cells and those infected with 
ring forms tend to aggregate and stack in rou­
leaux formations that sediment rapidly. Erythro­
cytes infected with more mature stages are 
usually deformed — losing their biconcave 
shape — and do not stack to form aggregates. 
Therefore, they remain in suspension due to 
the high viscosity of the gelatin solution. The 
advantage of the Plasmagel solution is its ready 
availability as a commercial plasma expander 
for clinical use (3% partially degraded gelatin 
in physiological saline). Another desirable cha­
racteristic of the Plasmagel preparation is its 
resistance to gelation when stored at 4°C, as 
happens with gelatin solutions. 
Another frequently used method for purify­
ing ring forms and young trophozoites is the 
sorbitol technique (MREMA et al., 1979). This 
compound destroys schizonts and mature tro­
phozoites, yet is innocuous to younger forms. 
Althrough the sorbitol technique is not an en­
richment method, it can be used alone or in 
conjunction with one of the gelatin techniques 
to obtain inocula to start synchronized cultures 
of P. falciparum. By the use of such homoge­
neous cultures, it is possible to obtain relatively 
pure suspensions of a single stage by harvesting 
at appropriate intervals after the inoculation of 
the culture. Unlike the infection in human or 
simian hosts, however, the parasite population 
tends to gradually lose synchronicity in the in 
vitro system. Therefore, harvest of parasite 
stages must be done during the cycles imme­
diately after inoculation with the ring forms. 
BILLIAULT and AMBROISE THOMAS 
(1980) devised a technique for isolating P. falci­
parum merozoites from cultivated parasites 
bound to concanavalin A. This technique may 
prove to be very useful for immunological 
studies. It is based on the principle that in­
fected cells (and normal red cells) bind and 
become attached to concanavalin A molecules 
that have been covalently linked to Sepharose 
4B beads in a column-packed assembly. Because 
parasite (merozoite) membranes lack the car­
bohydrate residues that bind to the lectin, they 
are not retained in the column, and thus are 
collected in the effluent. The merozoites are 
released by natural rupture of the mature schi­
zonts and exit the column with the void phase 
with minimal contamination. 
A major shortcoming of almost all isolation 
techniques has been contamination with host 
material. Red cell s tromata and other host 
substances — at best in trace amounts — are 
frequently harvested with the parasite antigen 
phase. Even when using a relatively mild iso­
lation technique such as the saponin method, 
free parasite suspensions will invariably contain 
host cell derived material, while presenting 
apparently acceptable cleanliness by microsco­
pical inspection. These host derived antigens 
may mask the immune response in vaccination 
studies and may even lead to autoimmune 
reactions. In serological reactions these host 
antigens may decrease sensitivity of the assay 
and may be a cause for nonspecific reactions. 
With the advent of recombinant DNA teen-
niques biosynthetically- produced plasmodial an­
tigens have been successfully expressed in bacte­
rial hosts. These geneticalry engineered peptides 
have been obtained by initial characterization 
of the amino acid sequence and reverse trans­
lation of
 m RNA segments into CDNA which is 
in turn transferred to bacterial hosts via a 
suitable vector (ANONYMOUS, 1982). Antigens 
produced in this manner represent an obvious 
advantage in terms of their cleanliness (with 
respect to host-derived substances) and availa­
bility in large quantities. It is expected that the 
techniques currently used to produce these 
peptides will be improved from the present 
state-of-the-art. This will allow the production 
of genomic libraries encoding larger antigenic 
proteins. As a derived benefit from the use of 
genetically translated antigens is the possibility 
of using nucleic acid probes for detection of 
circulating malarial antigens (FRANZEN et al., 
1984). These probes can hybridize with the 
correspondent parasite peptides present in the 
plasma of infected persons, thus allowing de­
tection of infection. 
Sérodiagnostic techniques. Serological tech­
niques as applied to a variety of diseases serve 
three main purposes: (i) to detect the presence 
of current infection, (ii) to detect past expe­
rience with the parasite, and (iii) to assess 
levels of protective immunity. The contribution 
of serological methods for the study of malaria 
has been limited to the second of the above 
purposes in the form of seroepidemiological 
surveys. Although serological techniques such 
as the indirect immunofluorescence (IIF) test 
can aid in presumptive diagnosis of current 
malarial infection, definitive diagnosis can only 
be made by demonstrating the parasite in 
smears of peripheral blood. In addition, de­
tection of protective immunity has only been 
achieved through the use of antibody-mediated 
bioassays of inhibition of in vitro growth of 
parasites (CAMPBELL et al., 1979); CHULAY 
et al., 1981; REESE and MOTYL, 1979). 
Sérodiagnostic methods have attained an 
importance second only to the more classical 
technique of examining stained blood slides in 
the diagnosis and epidemiology of malaria. In 
fact, serological testing has provided most of 
our present knowledge on the humoral immune 
response to malaria. 
Humoral response plays an important role 
in anti-malarial immunity. This role can be 
better exemplified by observing the course of 
infection in a nonimmune person traveling to 
a hyperendemic malarious area as compared to 
that in an immune native. The former will have 
high parasitemia and severe clinical symptoms 
which, especially in untreated P. falciparum, 
may prove lethal, whereas the native will.pro­
bably have low intermitent parasitemias with 
mild clinical symptoms. I t is unfortunate, ho­
wever, that despite this strong evidence for the 
role of protective antibodies, our state of the 
art in immunology of malaria can only empiri­
cally provide clues about individual levels of 
immunity. 
Ideally, sérodiagnostic tests should provide 
the same information as that obtained in the 
diagnosis of viral infections such as rubella and 
measles, where antibody titers often indicate 
the presence of effective immunity. In the 
case of malaria and many other diseases caused 
by eukaryotic organisms, antibody response is 
complex and, expectedly, represents a combina­
tion of monoclonal responses against a large 
variety of antigens of differing degrees of re­
levance to the welfare of the parasite. Ideally, 
for estimation of the immune state, only protec­
tive antibodies should be detected. These are 
the antibodies that compromise the survival of 
the parasite, presumably, by combining with, 
and inactivating some essential antigen com* 
ponent of the cell. 
The only available tests for evaluation of 
protective immunity are bioassays based on 
antibody mediated inhibition of parasite growth 
in vitro. Such tests were originally proposed 
(MITCHELL et al., 1976; WILSON and 
PHILLIPS, 1976) as empirical approaches for 
detection of anti-plasmodial antibody responses 
that could impair maturation of P. faciparum 
in vitro. With the advent of continuous culture 
techniques for this parasite species those tests 
were also used to detect antibody mediated 
inhibition of merozoite invasion of erythrocytes 
(BROWN et al., 1982; CHULAY et al., 1981; 
EPSTEIN et al., 1981; REESE and MOTYL, 
1979; VER-NES et al., 1984). 
Although not correlating with protective 
immunity, the serological techniques that have 
been more or less successfully applied to the 
detection of antimalarial antibodies in human 
seia are the indirect hemaggluttination test 
(IHA), the indirect immunofluorescence (IIP) 
test (also designated as indirect fluorescent 
antibody test: IPA), and the enzyme linked 
immunosorbent assay (ELISA) (also as enzyme 
immunoassay: EIA). The latter two tests are 
considered to be immunoassays since they 
employ second antibodies (usually in labeled 
form) as an indicator system. The IHA test 
expresses antigen-antibody binding directly by 
increased adhesiveness of the coated cells which 
leads to visually detected agglutination. 
The IHA test has been used extensively for 
seroepidemiological purposes (KAGAN et al., 
1969; VOLLER and DE SAVIGNY, 1981). Ori­
ginally, P- berghei antigen was used in the test 
for the detection of antibodies in homologous 
antisera (DESOWITZ and STEIN, 1962). I n the 
initial system there was already an attempt to 
provide long lasting reagents by the use of 
formol and tannic acid-treated sheep erythro­
cytes (STEIN and DESOWITZ, 1964). Results 
with this early system were reviewed by KAGAN 
et al. (1969). Various problems in executing the 
test were soon realized, such as lack of repro­
ducibility due to variations in reagent batches, 
autoagglutination of cells, and nonspecific agglu­
tination factors in sera. Introduction of techni­
cal variants gradually improved the test. These 
included the use of antigens from simian pa­
rasites (LUNDE and POWERS, 1976; WILSON 
et al., 1975; WILSON et al., 1971) or even 
better antigens from human malarial parasites 
(MEUWISSEN et al., 1974; VOLLER et al., 1974) 
that had been grown in AOTUS monkeys or 
extracted from infected human placentas. Other 
refinements included the use of lyophilized cells, 
double aldehyde fixation, and serum adsorption 
with red cells coated with extracts of cells 
from noninfected monkeys to reduce nonspe­
cific reactions (DRAPER and AKOOD, 1983). 
In two comprehensive studies comparing the 
IHA and the I IP tests (1971), and later the 
complement fixation (CP) test to both the IIF 
and IHA tests (1975), WILSON et al. demons­
trated that the latter tests were of superior 
sensitivity as compared to the CF test; these 
comparisons were made using sera from U.S 
veterans from Vietnam. 
MEUWISSEN et al. (1974), testing sera 
from an endemic area in Africa, showed that 
the IHA yielded twice as many nonreactors as 
the I IF . A major pitfall of the IHA test was 
pointed out by VOLLER et al. (1974). The test 
was defective in revealing antibody patterns in 
children living in endemic areas. The Authors 
expressed fear that surveys based solely on 
this test could yield misleading results by 
underestimating the number of infected young 
children. One possible explanation for this lack 
of sensitivity is that the antibodies produced 
in the child's response to the infection would 
be of lower affinity, although this has not been 
proven experimentally. 
The IHA test has always been plagued by 
a number of seemingly insurmountable pro­
blems. Despite its simplicity of execution, the 
test is primitive in both interpretation and 
performance. As does the CF test, which was 
purposely omitted in this discussion, the IHA 
test uses reagents of animal origin (erythrocy­
tes and diluent serum) and, thus, is difficult 
to standardize. In addition, this test, as well 
as others of earlier generations in serology, is 
interpreted subjectively and is not easily auto­
mated. Possibly the IHA test will eventually be 
replaced by the ELISA test which as the former, 
uses soluble antigens and is rapidly executed 
but, unlike the IHA, can be interpreted objecti­
vely. 
The IIF test was used originally for direct 
diagnosis of malaria by detecting parasites in 
blood slides (BROOKE et al., 1959). The test 
as it is known today was first used by KUVIN 
et al. (1962). The early history of the I IF test 
has been presented in a review by SULZER and 
WILSON (1971). An initial difficulty was pre­
sented by antibodies in the antigen donor's 
plasma that could react autologously with the 
antigen. To avoid autologous reaction between 
the donor's antibodies in the serum and the 
antigen preparation, parasitized blood had to 
be drawn from donors before appearance of 
antibodies (SODEMAN and JEFFERY, 1966). 
This reduced the number of blood smear 
donors available. Gamma globulin in the donor's 
serum often coated the slide producing back­
ground staining with the anti-species conjugate 
and consuming a fraction of its activity. This 
secondary staining due to the conjugate reaction 
with the plasma globulin in the preparation was 
prevented by a technical variant proposed by 
COLLINS and SKINNER (1972). They used 
dilute hydrochloric acid to lyse erythrocytes, 
fix the antigen, and remove the donor's plasma 
from the slides prior to reacting with serum. 
Although this procedure seems to provide good 
results in eliminating the background reaction, 
it may also remove or inactivate some acid-
sensitive antigenic determinants from the pre­
paration which reduces test sensitivity. It 
seems, however, that the acid-lysis technique 
has been largely accepted. 
A method to circumvent the problem of 
background nonspecific reactions was provided 
by SULZER and WILSON (1967) and SULZER 
et al. (1969). Their approach was strikingly 
simple. Since only the parasitized red cells are 
required in the test, plasma proteins can be 
removed by washing the cells in buffered saline 
in a few centrifugation cycles. Any antibody in 
the antigen donor's serum is removed before 
it can react with the antigen. Since the presence 
of specific antibody in the donor's serum is 
no longer of any concern, this procedure in­
creases the number of potential donors of 
parasitized blood for the test. Because nonspe­
cific staining was no longer a problem, thick 
smears could be made, which effectively con­
centrated the parasites and thus reduced time 
required to read tests. Another derived benefit 
was the possibility of using blood samples with 
low parasitemia which would otherwise be 
unsuitable for the thin smear technique. 
Another phenomenon that was soon noticed 
by serologists was the variation in results 
obtained when using different antigen species. 
Reactions were more intense and to greater 
titer in homologous systems, i.e., when using 
antigens derived from the same malarial species 
that caused the infection in the donor of the 
serum being tested (GLEASON et al., 1971; 
SALATA et al., 1981; SULZER and WILSON, 
1971; SULZER et al., 1973; VOLLER, 1977). This 
led to a number of variants according to the 
antigen species used in the test. For many 
laboratories, availability of malarial parasites 
from either simian or human hosts is an acute 
problem and, hence, many resorted to the use 
of rodent malarias such as P. berghei which can 
be easily maintained through passages in mice 
or rats (MAIER and PIEKARSKI, 1979; SALATA 
et al., 1981), or even avian malaria parasites 
such as P. gallinaceum (GIACOMETTI and 
SUTER-KOPP, 1972; KIELMAN and WEISS, 
1968). Simian-host malarial parasites seem to 
provide the most satisfactory reagent since 
cross reactivity between simian and human pa­
rasites is usually much higher than that of 
human compared to rodent or avian malarial 
parasites. P. knowlesi has been the preferred 
simian parasite when none of the human ma­
larial antigen preparations is available (CHAN-
DANARI et al., 1981; COLLINS et al., 1966). 
With the increasing scarcity of non-human pri­
mates for biomedical purposes, very few la­
boratories in the world can use entirely ho­
mologous antigen sets in their tests. This 
problem led one laboratory to propose the 
creation of a malarial antigen distribution cen­
ter to supply IIF slides of all four human 
malarias on a regular basis to serology la­
boratories devoted to the diagnosis of malaria 
(SULZER, 1975). 
A more suitble source of variability in the 
IIF test (and also other tests) has been re­
presented by the relative abundance of the dif­
ferent erythrocytic stages of the parasite that 
are present in the antigen. Earlier studies had 
mentioned the greater reactivity of more ma­
ture stages of the parasite with most human 
sera (SODEMAN and JEFFERY, 1966; SULZER 
et al., 1969). In a more detailed study, TARGETT 
(1970) corroborated these observations by using 
an elegant protocol that compared P. falciparum 
antigen "in natura" as obtained from the in­
fected blood against a portion of the same an­
tigen that had been matured in vitro to the 
point of greater abundance of schizonts. Titers 
were dramatically higher when using the ma­
tured antigen. Targett's choice of P. falciparum 
as antigen in the study highlighted the problem 
of the scarcity of schizonts in the peripheral 
blood of infected hosts. It has been known for 
many years that schizonts of P. falciparum se­
quester in deep tissues prior to schizogony, 
therefore early trophozoites are the stage most 
commonly seen in the blood. The importance 
of using a matured homologous antigen system 
for diagnosis of malaria, although dramatic, has 
been taken into consideration by only a few 
investigators C AMBROISE-THOMAS et al., 1974). 
Paradoxical observations in the early literature 
— such as the fact that heterologous reactions 
may be greater than homologous reactions in 
simian malarias (COLLINS et al., 1965) — may 
have been due to lack of equal abundance of 
more mature stages in the i antigens utilized. 
As a result of their concern with the problem, 
SULZER and LA TORRE (1977) developed a 
method for the maturation of parasites in blood 
which is applicable to all four human malarial 
species. This method, further evaluated by 
FRANCO and SULZER (1983), enables seroio-
gists to prepare optimally matured antigens for 
evaluating infections at the species level on 
the assumption that, once differences in stage 
reactivity among the four antigens are aboiisn-
ed, only species-specific antibodies would play 
a role in causing differences among titers. More 
recently, P. falciparum antigens obtained from 
in vitro cultures have been used in the I IF or 
other tests (GUPTA et al., 1981; HALL et al., 
1978). I t is unfortunate, however, that conti­
nuous cultivation in vitro is not possible for 
the other three species of human malarial para­
sites which would obviate the need to maintain 
parasites in nonhuman primates or to depend 
on infected human subjects as a source of 
antigen preparations. 
The ELISA technique was originally intro­
duced as an alternative to radioimmunoassay 
(ENGVALL and PERLMANN, 1971) and was 
later adapted to the serology of malaria in 1974 
by VOLLER et al. Since its introduction this 
test has acquired importance in the seroepide-
miology and immunology of malaria (TANDOM 
et ai., 1982). The great advantage of the ELISA 
technique is its short execution time which 
makes it a convenient test in assaying large 
numbers of specimens simultaneously. Of the 
various tests described for malaria serology 
the ELISA is the one most likely to supplant 
the I IF test due to the comparable sensitivity 
and specificity that this test exhibits to the 
latter (DRAPER and AKOOD, 1983). The prin­
ciple governing the degree of response in the 
ELISA is analogous in design to the I IF test 
since both are immunoassays (serological tests 
that use a second antibody). Nevertheless, a 
great deal of commonality also exists between 
the ELISA and the I HA since both tests are 
based on selective binding of antibodies to so­
luble antigens of the parasite. 
A crude extract of P. knowlesi-infected 
blood from monkeys was used in the first stu­
dies on ELISA in malaria diagnosis (VOLLER 
et al., 1975). Since then, a variety of antigens 
from several host systems has been used. The 
more successful combinations include sonicated 
F. falciparum extracts from matured (VOLLER 
et al., 1974) Aotus blood (BIDWELL and 
VOLLER, 1981; QUAKYI, 1980; VOLLER et al., 
1980), sonicated P. falciparum extracts from 
continuous cultures (SPENCER et al., 1979; 
SPENCER et al., 1979) and from infected pla­
centas (QUAKYI, 1980), and the originally pro­
posed system of sonicated P. knowlesi antigen 
from infected blood of rhesus monkeys (TAN-
DOM et al., 1982; VOLLER et al., 1975). 
At present it is not wise to draw conclu­
sions about any particular behavior of the 
ELISA as compared to the IIP test regarding 
sensitivity and specificity. Because enzyme im­
munoassays in general represent a relatively 
novel approach in serology, several problems 
that are intrinsic to the ELISA test must be 
solved, such as purification of antigen, and 
standardization of solid phases and antibody-
enzyme conjugation. Problems that have arisen 
through the use of the ELISA are lack of sen­
sitivity and/or specificity (particularly in test­
ing specimens from younger age groups), and 
poor reproducibility (DRAPER and AKOOD, 
1983). Despite these shortcomings, ELISA is 
the only diagnostic system besides radioimmu­
noassay that can objectively measure antibody 
activity in specimens, since there is a conti­
nuum o results provided by colorimetric read­
ing. This represents a great analytical advantage 
as compared to tests based on titers which are 
geometrically spaced, e.g., I IP and IHA. This 
characteristic of enzyme immunoassays makes 
them potentially useful tools for all areas of 
malaria immunology, particularly in the recen­
tly expanded field of hybridoma technoloy. 
Use of hybridoma-derived monoclonal anti­
bodies is likely to bring new perspectives in 
serological testing. These monospecific antibo­
dies bind to a single antigenic moiety and, 
hence, through their use one is able to distin­
guish between background reactivity in a given 
assay and genuine antigen sharing among para­
sites (MITCHELL et al., 1979). 
PROCEDURES 
In vitro cultivation of P. falciparum. For 
the cultivation of P. falciparum in human ery­
throcytes the Jensen-Trager candler jar method 
is used. Parasites are cultivated as 10% infec­
ted-cell suspensions in RPMI 1640 medium 
(GIBCO Laboratories, Grand Island, NY) sup­
plemented with 10% group O, Rh+ human se­
rum, 30 raM HEPES buffer, and 0.6 M NaHC0 3 . 
Cultures are usually started as 0.5 ml suspen­
sions in 24-well flat bottom plastic plates. The 
medium is changed daily and thin smears are 
prepared and stained with Giemsa for the eva­
luation of the percentages of infected cells and 
determination of parasite stages. When appro­
ximately 4-5% of the erythrocytes are parasitiz­
ed, cultures are diluted 4-5 fold by the addition 
of washed noninfected human erythrocytes as 
a 10% suspension in the above medium. For 
larger culture suspension volumes either 5 or 
10 ml capacity Petri dishes are used instead of 
the multi well plates. Cultures are incubated 
at 37°C in gas-tight jars under reduced 0 2 ten­
sion and elevated C0 2 concentration as in the 
original candle flame extinction procedure. 
Enrichment of infected-cell suspensions. 
Suspensions of infected erythrocytes obtained 
from in vitro culture are aseptically made in 
eitner gelatin or Plasmagel to allow separation 
of red cells infected with older trophozoites 
and schizonts from noninfected and ring-con­
taining cells. Basically, culture-derived cells 
are washed once in culture medium by centri­
fugaron to remove cell debris and resuspended 
again in fresh medium as a 25% suspension. 
An equal volume of prewarmed (37° C) gelatin 
(Sigma Chemical Co., St. Louis, MO) or Plas­
magel (HTI Corporation, Buffalo, NY) solu­
tion is added. The suspension is gently, but 
throughly mixed and incubated at 37°C in a 
water bath for 30 min. Tubes used for this in­
cubation step are never filled with more than 
the volume of suspension necessary to provide 
a fluid height of 10 cm. Because the efficacy of 
the procedure is based on differences between 
settling speeds of noninfected (and ring-infect­
ed) and older stage-infected cells height, and 
not volume, of fluid is a critical variable in the 
procedure. Following incubation, tubes are gen­
tly removed from the water bath and the upper 
phases of the suspensions are transferred with 
a Pasteur pipette to a separate tube (taking 
care not to disturb the sedimented erythrocy­
tes) . Cells from this top layer are sedimented 
by centrifugation at 1,000 x G for 10 min and 
resuspended in an equal volume of fresh cold 
medium. For the evaluation of the percentage 
of infected red cells, smears are made and 
stained for microscopical examination. The 
bottom layers remaining in the original incu­
bation tubes can be either discarded or frozen 
in liquid N 2 following the addition of 10% di­
methyl sulfoxide (DMSO) (Baker Chemical Co., 
Phillipsburg, NJ) . These are retained as para 
type stock cultures for further reference. 
Preparation of antigen slides of P. falcipa­
rum. P. falciparum infected-cell thick smears 
are made in multi-well glass slides for use with 
the IIF test as follows: Plasma-gel-enriched sus­
pensions are washed once in PBS (pH 7.6, 
0,01 M) and resuspended at 10% in the same 
buffer. The density of parasites per 1,000 X 
microscopic field is then recorded following 
staining of trial thick smears made in one mul­
ti-well slide. If the density is outside the range 
of 5-50 parasites per field the suspension can be 
concentrated or diluted properly to allow uni­
form parasite density. Slides are prepared (12-
well slides) by allowing thick films of the sus­
pensions to air dry at room temperature. Sli­
des are coded, wrapped in paper and stored 
in vapor phase over liquid N 2 until used. Giem-
sa-stained slides of all isolates are kept for 
each of the three steps of the procedure: (i) 
culture, (ii) Plasmagel-enriched suspension, and 
(iii) thick smear on 12-well slide. 
Extraction of soluble P. falciparum antigen. 
For the enzyme immunoassay (EIA) reactions 
enough antigen material is obtained from lar­
ge culture volumes (10 ml Petri dishes). The 
untreated culture suspension to be used in the 
preparation of EIA antigen should range in 
volume between 80 and 100 ml. Following en­
richment with Plasmagel, infected cells are 
washed once by centrifugation in could incom­
plete culture medium (without serum and 
NaHC0 3 ) at 1,500 x G for 15 min. The super­
natant is discarded and 5 ml of a solution 
containing 0.04% saponin in incomplete medium 
is added to the brownish pellet of cells. Follow­
ing brief homogenization by vortex-mixing the 
suspension is incubated at room temperature 
for 20 min to allow lysis of red cells. The sus­
pension is then centrifuged at 1,500 x G for 15 
min to allow sedimentation of parasites. The 
hemoglobin-tinted supernatant is discarded and 
the pellet resuspended in 12 ml of cold incom­
plete medium. After another identical centri­
fugation cycle the supernatant is discarded and. 
the pellet frozen at -20°C for periods not exceed­
ing four days. 
Pellets are resuspended in 2 ml of cold ex­
tracting buffer (PBS pH 7.2, 0.01 M or 8 M 
urea in the same buffer) and exposed to 300 
Watt ultrasonic pulsed oscillations (Sonifier 
Cell Disrupter, Heat Systems Ultrasonics, Inc., 
Plainview, NY) with a microtip transmitter for 
times ranging between three and four minutes 
with 30 second idle intervals for every 30 se­
conds of sonication. The tube containing the 
suspension is immersed in an ice water bath 
during the entire sonication procedure. The 
resulting dark solution is then centrifuged for 
15 min at 12,100 x G and 4°C. After centrifuga­
tion the yellowish supernatant is carefully re­
moved and transferred to a gas-thight plastic 
vial and stored in vapor phase over liquid N 2 
until assayed. The black pellet in the bottom 
of the tube is composed mostly of malarial 
pigment and cell debris and, therefore, can be 
discarded. 
To determine the protein concentration 
Lowry or Bradford techniques can be used. 
Because these procedures differ in principle a 
standard curve should be prepared to allow 
derivation of results using the linear regression 
estimates by the least-squares method. 
Indirect immunofluorescence (IIF) test. 
The basic method is that of SULZER et al. 
(1969) with some modifications: Specimens to 
be tested are used either undiluted (for screen­
ing purposes) or serially diluted in PBS, pH 7.6. 
Antigen slides are brought to room temperatu­
re immediately prior to use. To avoid water 
condensation on smears, slides are exposed to 
an air current provided by a fan for about 
15 min. Drops of approximately 0.02 ml of 
each specimen are dispensed into antigen wells 
using a Pasteur pipette. Slides are then placed 
on a tray containing a moist piece of tissue 
paper, covered, and incubated for 30 min at 
37°C. Slides then are flooded with PBS, washed 
once by dipping for about 30 sec in the same 
solution, and air dried using a fan. To reveal 
antibody binding, fluorescein (FITC) — labelled 
anti species antibody conjugate (Tago, Inc., 
Burlingame, CA) (diluted in PBS containing 
0.5% Evans blue, as a counterstain) is dispens­
ed on the slide wells (approximately 0.02 ml 
drops). Slides are placed in the humid tray 
and incubated again as described above. Follow­
ing another washing cycle, slides are air dried 
and covered with mounting fluid (a 1:9 mixtu­
re of 0.2 M Na^HPOj, pH 9.0 and glycerol) and 
cover slips. To evaluate reactivity, slides are 
examined with a microscope (American Opti­
cal) equipped with a mercury vapor (HBO 50) 
epiilluminator, an 2077 fluorocluster, and oil 
immersion objectives. Intensity of fluorescing 
organisms per field (1,000 x) are recorded for 
each preparation. 
Enzyme immunoassay (EIA). EIA reactions 
are performed in flat-bottomed, 96-well polys-
tyrene plates ( immulon 2, Dynatech Labora-
tories, Inc., Alexandria, VA). Plates are sensitiz-
ed with P. falciparum soluble antigen extract 
(prepared as described above) diluted in PBS 
7.2 (adjusted to 1-10 mg/L of protein concen-
tration). Fifty microlisters of freshly diluted 
antigen extract are dispensed into all wells. 
Plates are vibrated using a plate vibrator (Tho-
mas Shaking Apparatus, Arthur H. Thomas Co., 
Philadelphia, PA) to allow formation of uni-
form coating areas for all wells — and sealed 
with adhesive tape. Incubation follows in two 
phases: first, for 2 hr at 37°C in a water bath 
(with the water level preadjusted to prevent 
flotation of plates, yet allowing all well bottoms 
to be in contact with water) and, second, over-
night at4°C. 
Prior to assay, specimens are brought to 
room temperature and vortex-mixed. Plates are 
removed from the refrigerator, unsealed, and 
the antigen solution is removed by inverting 
and shaking. Plates are then washed for three 
cycles of 3 min each by filling all wells with PBS 
pH 7.2 containing 0.05% Tween 20 (PBS-Tw) 
supplied by an 8 channel manifold fitted to a 
Cornwall syring that is connected to a solution 
reservoir. The use of the manifold allows all 
wells to be flooded with equal stream pressure. 
Removal of PBS-Tw is done by inverting and 
shaking. To remove the last possible traces of 
moisture from the wells each plate is inverted 
and struck sharply 10 15 times against a paper 
towel spread on a laboratory bench. Fifty ul 
of undiluted or serially-diluted specimens (in 
PBS-Tw supplemented with 1% BSA (PBS-Tw-
BSA) are added to each well by means of an 
automatic 8-channel pipette (Flow Laboratories, 
Inc., Mc Lean, VA). Plates are incubated for 
30 min at 37°C in a water bath as described 
above. Specimens are removed and plates wash-
ed as above and shaken dry. Previously diluted 
(in PBSTw-BSA) peroxidase (Donor: H 2 0 2 oxi-
doreductase, EC 1.11.1.7, horseradish) labelled 
anti-antibody conjugate (specific for the anti-
body donor and heavy chain type) (Tago, Inc., 
Burlingame, CA) is added (0.05 ml) to each 
well. Following another incubation and washing 
cycle, solid-phase bound enzyme is revealed by 
adding 0.05 ml of a freshly prepared solution 
of substrate-chromogen (0.1 mg/ml o-phenyle-
nediamine and 0.003% H 2 0 2 in acetate buffer, 
pH 4.5) . Plates are then incubated at room 
temperature for 30 min in the dark and subs-
trate catalysis is stopped by addition of. 0.025 
ml/well of 4 M H 2 S0 4 . The well contents are 
mixed by vibration, the bottom of the plates 
are wiped with soft absorbent paper and co-
lorimetric readings (490 nm) are taken using 
a computer — interfaced plate reader (MR-580, 
Dynatech Laboratories, Inc., Alexandria, VA). 
RESUMO 
Imuno-sorologia da malária 
Neste trabalho são revistos os métodos so¬ 
rodiagnósticos mais frequentemente utilizados 
para a determinação da resposta imune humo-
ral aos parasitas da malária. A importância 
desta doença como um problema mundial de 
saúde pública é enfatizada à luz das novas des-
cobertas no campo imunológico que poderão 
culminar no desenvolvimento de uma vacina 
adequada para uso humano. A aplicação de téc-
nicas sorológicas certamente será de extrema 
importância na avaliação da eficácia relativa 
destas potenciais vacinas. Discute-se também, 
no presente trabalho, as diferentes técnicas de 
preparação de antígenos. 
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